Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine

NCT05433285 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

4050

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: COVID-19 Protein Subunit Recombinant Vaccine
BIOLOGICAL: Active Comparator

Sponsor

PT Bio Farma

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]